Clinical trials: Benign Hyperplasia of Prostate
Benign Prostatic Hyperplasia
Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia
This study is a randomized, double-blind, placebo and tamsulosin-controlled, parallel design, multinational study to evaluate the efficacy and safety of Tadalafil once-a-day dosing for 12 weeks in Asian men with signs and…
- Trial name
- NCT00861757
- Testing
- Tadalafil, Tamsulosin
- Where
- 6 sites in Japan, Taiwan
- Volunteers
- 612 people
- Sponsor
- Eli Lilly and Company
Prostatic Hyperplasia
Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)
The purpose of this study is to determine if transurethral photodynamic therapy with lemuteporfin has a therapeutic effect on lower urinary tract symptoms due to an enlarged prostate.
- Trial name
- NCT00116571
- Testing
- Lemuteporfin for injection, Transurethral drug delivery system, Transurethral light delivery system
- Where
- 9 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- QLT Inc.
Overactive Bladder, Benign Prostate Hyperplasia
Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)
The purpose of this study is to demonstrate superiority of the solifenacin succinate (treatment) over the placebo (control) based on the change from the baseline in the mean number of urgency episodes per 24 hours after 2 weeks.
- Conditions
- Overactive Bladder, Benign Prostate Hyperplasia, Transurethral Resection of Prostate, Photoselective Vaporization Prostatectomy
- Trial name
- POST-TURP (NCT01747577)
- Testing
- Solifenacin Succinate
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Astellas Pharma Korea, Inc.
Benign Prostate Hyperplasia
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With BPH
The main objective of this study is to evaluate efficacy and safety of (Tamsulosin) HGP0412 and HIP1402 in patients with Benign Prostatic Hyperplasia
- Trial name
- NCT02390882
- Testing
- HGP0412 capsule, HIP1402 capsule
- Where
- South Korea
- Volunteers
- 494 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Moderate-to-severe Benign Prostatic Hyperplasia (BPH)
Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fed Conditions
To evaluate and compare the safety and pharmacokinetic profiles of "AJU-G721" (test drug) and "G721R" (reference drug) in healthy adult male subjects.
- Trial name
- NCT07643233
- Testing
- Test Drug, Reference Drug
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AJU Pharm Co., Ltd.
Lower Urinary Tract Symptoms, Prostatic Hyperplasia
Efficacy and Safety of Longidaze in the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
The goal of this clinical trial is to learn if Longidaze works to treat lower urinary tract symptoms in adult males with benign prostatic hyperplasia. It will also learn about the safety of Longidaze.
- Trial name
- ADAM (NCT06568718)
- Testing
- bovhyaluronidase azoximer, tamsulosin
- Where
- 3 sites in Russia
- Volunteers
- 229 people
- Sponsor
- NPO Petrovax
Prostatic Hyperplasia
SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin
Primary Objective: To assess the sexual function improvement from baseline to the end of treatment (Week 24 or premature withdrawal (PW)) with XATRAL 10mg OD.
- Trial name
- NCT00486785
- Testing
- Alfuzosin
- Where
- 4 sites in Colombia, Ecuador and 2 more
- Volunteers
- 431 people
- Sponsor
- Sanofi
Benign Prostatic Hyperplasia
Urodynamic Feasibility Study Utilizing the UroLift® System
UDS evaluates the impact of Prostatic Urethral Lift (PUL) as measured by pressure flow, urodynamic testing (UDS) and an optional UroCuff Testing, an alternative urodynamic test.
- Trial name
- UDS (NCT04271020)
- Testing
- UroLift
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- NeoTract, Inc.
Prostate
Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement
The primary objectives were to determine the efficacy and safety of the GITS formulation of Doxazosin in Taiwanese patients with prostate enlargement.
- Trial name
- NCT00648323
- Testing
- Doxazosin mysylate GITS
- Where
- 4 sites in Taiwan
- Volunteers
- 80 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Overactive Bladder
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment…
- Trial name
- NCT04103450
- Testing
- Vibegron
- Where
- 35 sites in United States, Poland
- Volunteers
- 276 people
- Sponsor
- Urovant Sciences GmbH
Prostatic Hyperplasia
Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia
Study to describe Tamsulosin prescription characteristics in a representative population of patients on treatment for benign prostatic hyperplasia
- Trial name
- NCT02245555
- Testing
- Tamsulosin
- Volunteers
- 1,060 people
- Sponsor
- Boehringer Ingelheim
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms
The hypothesis of the study is to examine whether MCS-2 is safe and effective in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
- Trial name
- MCS_LUTS (NCT01002664)
- Testing
- MCS-2
- Where
- Taiwan
- Volunteers
- 272 people
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
Benign Prostatic Hypertrophy
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Benign Prostatic Hypertrophy (BPH) is a common and bothersome condition of aging men. It is characterized by an enlargement of the prostate occurring in human male over the age of 50 which increases in prevalence with age, and…
- Trial name
- NCT00449150
- Testing
- Cetrorelix 78 mg + 78 mg, Cetrorelix 78 mg + 52 mg
- Where
- 68 sites in United States, Bulgaria and 2 more
- Volunteers
- 667 people
- Sponsor
- AEterna Zentaris
Benign Prostatic Hyperplasia (BPH)
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
This study will evaluate the safety and efficacy of a 2.5 mg dose of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) as compared to placebo.
- Trial name
- NCT00945490
- Testing
- NX-1207
- Where
- 35 sites in United States
- Volunteers
- 500 people
- Sponsor
- Nymox Corporation
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)
This is an open-label extension study of another study protocol, MCS-2-US-a. Subjects who have completed the 12-week treatment and procedures under the protocol MCS-2-US-a will be eligible for this study.
- Trial name
- MCS-2-US-c (NCT01002222)
- Testing
- MCS-2
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
Benign Prostatic Hyperplasia
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
- Trial name
- NCT00224120
- Testing
- Silodosin
- Where
- 42 sites in United States
- Volunteers
- 462 people
- Sponsor
- Watson Pharmaceuticals
Benign Prostatic Hyperplasia, Adenoma, Prostatic
Rezum FIM Optimization Study
Evaluate the effect of the NxThera BPH Rezum System on prostate tissue in subjects suffering from LUTS symptoms secondary to benign prostatic hyperplasia (BPH).
- Conditions
- Benign Prostatic Hyperplasia, Adenoma, Prostatic, Prostatic Adenoma, Prostatic Hyperplasia, Benign
- Trial name
- Rezum FIM (NCT02940392)
- Testing
- Rezum System
- Where
- Dominican Republic
- Volunteers
- 15 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
This study investigates the safety and efficacy of a photosensitive drug (talaporfin sodium) activated by an intraurethrally placed drug-activating device.
- Trial name
- NCT02326454
- Testing
- talaporfin sodium, Saline, Drug Activator 100 J/cm
- Where
- 41 sites in United States
- Volunteers
- 225 people
- Sponsor
- Light Sciences Oncology
Benign Prostatic Hyperplasia
Evaluation of the Water Vapor Thermal Therapy System for the Treatment of Benign Prostatic Hyperplasia
To evaluate the efficacy and safety of the Water Vapor Thermal Therapy system for the treatment of Benign Prostatic Hyperplasia under the premise of ensuring the safety of the subjects and ensuring the scientific nature of the…
- Trial name
- NCT06725212
- Testing
- Water Vapor Thermal Ablation, Cystoscopy
- Where
- 10 sites in China
- Volunteers
- 126 people
- Sponsor
- Medtecx Co Ltd.
Prostatic Hyperplasia
Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients
Study to evaluate the therapeutic effect of tamsulosin and finasteride in symptomatic BPH patients, two medications indicated in BPH belonging to two different pharmacological classes, as evaluated from the point of view of…
- Trial name
- NCT02244229
- Testing
- Tamsulosin, Finasteride
- Volunteers
- 403 people
- Sponsor
- Boehringer Ingelheim